Kymera Therapeutics (NASDAQ:KYMR) Sets New 12-Month High at $49.06

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s share price reached a new 52-week high on Wednesday . The company traded as high as $49.06 and last traded at $48.52, with a volume of 410718 shares trading hands. The stock had previously closed at $46.50.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on KYMR. Morgan Stanley upped their price objective on Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 14th. Wells Fargo & Company raised their price objective on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. B. Riley boosted their price objective on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a report on Tuesday, July 9th. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 target price on shares of Kymera Therapeutics in a report on Monday, June 17th. Finally, Oppenheimer reissued an “outperform” rating and set a $52.00 price target on shares of Kymera Therapeutics in a research note on Wednesday, July 10th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $45.90.

Kymera Therapeutics Stock Performance

The business has a fifty day simple moving average of $38.58 and a 200 day simple moving average of $37.70. The stock has a market cap of $2.98 billion, a price-to-earnings ratio of -19.55 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.10. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The business had revenue of $25.60 million for the quarter, compared to analyst estimates of $12.55 million. During the same quarter last year, the company earned ($0.67) earnings per share. The business’s revenue for the quarter was up 55.2% compared to the same quarter last year. On average, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.86 EPS for the current fiscal year.

Insider Activity

In other Kymera Therapeutics news, insider Jared Gollob sold 23,145 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $45.81, for a total transaction of $1,060,272.45. Following the transaction, the insider now owns 95,470 shares of the company’s stock, valued at approximately $4,373,480.70. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of Kymera Therapeutics stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total value of $17,345,811.60. Following the transaction, the director now owns 723,246 shares in the company, valued at approximately $27,635,229.66. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jared Gollob sold 23,145 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $45.81, for a total transaction of $1,060,272.45. Following the sale, the insider now directly owns 95,470 shares of the company’s stock, valued at $4,373,480.70. The disclosure for this sale can be found here. Insiders sold a total of 502,345 shares of company stock valued at $19,279,932 over the last 90 days. Insiders own 15.82% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its position in Kymera Therapeutics by 18.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock valued at $254,548,000 after buying an additional 996,300 shares in the last quarter. BVF Inc. IL raised its stake in shares of Kymera Therapeutics by 8.9% in the 4th quarter. BVF Inc. IL now owns 5,161,801 shares of the company’s stock valued at $131,419,000 after acquiring an additional 422,797 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Kymera Therapeutics by 19.2% during the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after acquiring an additional 769,486 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in Kymera Therapeutics by 3.0% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,888,888 shares of the company’s stock worth $156,333,000 after purchasing an additional 113,888 shares during the period. Finally, Artal Group S.A. increased its holdings in Kymera Therapeutics by 19.6% in the 1st quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after purchasing an additional 496,400 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.